Tango Therapeutics, Inc.

NasdaqGM:TNGX Stock Report

Market Cap: US$780.2m

Tango Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?


Recent Insider Transactions

NasdaqGM:TNGX Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
20 Feb 24SellUS$1,950,000Third Rock Ventures, LLCCompany162,500US$12.00
07 Feb 24SellUS$46,900Daniella BeckmanIndividual3,725US$12.62
07 Feb 24SellUS$115,052Barbara WeberIndividual9,138US$12.62
07 Feb 24SellUS$105,395Adam CrystalIndividual8,371US$12.62
07 Feb 24SellUS$34,951Douglas BarryIndividual2,776US$12.62
01 Nov 23SellUS$62,994Adam CrystalIndividual7,507US$8.39
16 Oct 23BuyUS$8,722,500Tavistock Life SciencesCompany1,250,000US$7.07
09 Oct 23SellUS$495,500MVA Associates, LLCCompany50,000US$9.91
09 Oct 23SellUS$1,744,750Tavistock Life SciencesCompany175,000US$9.97

Insider Trading Volume

Insider Buying: TNGX insiders have only sold shares in the past 3 months.


Ownership Breakdown

What is the ownership structure of TNGX?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders1,657,9721.53%
Public Companies4,854,4434.48%
Private Companies7,695,1837.1%
Hedge Funds13,330,73612.3%
VC/PE Firms32,934,09730.4%
Institutions47,878,85144.2%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 21%.


Top Shareholders

Top 25 shareholders own 93.69% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
18%
Third Rock Ventures, LLC
19,201,475US$140.4m-0.84%54.97%
12.5%
EcoR1 Capital, LLC
13,330,736US$97.4m52.9%3.14%
9.17%
FMR LLC
9,787,350US$71.5m-16%no data
7.68%
Tavistock Life Sciences
8,198,642US$59.9m14.7%3.68%
6.55%
BCTG Holdings, LLC
6,988,450US$51.1m0%no data
5.18%
Nextech Invest Ltd.
5,533,980US$40.5m0%7.42%
4.94%
Southpoint Capital Advisors LP
5,276,699US$38.6m0%0.75%
4.55%
Gilead Sciences, Inc.
4,854,443US$35.5m0%no data
3.7%
BlackRock, Inc.
3,949,276US$28.9m11%no data
3.19%
Adage Capital Management, L.P.
3,400,000US$24.9m93.8%0.05%
2.79%
The Vanguard Group, Inc.
2,979,212US$21.8m1.34%no data
2.71%
Bain Capital Life Sciences Investors, LLC
2,892,663US$21.1m0%2.09%
1.84%
RTW Investments, LP
1,966,752US$14.4m0%0.26%
1.44%
Deerfield Management Company, L.P. Series C
1,540,000US$11.3m94%0.24%
1.3%
Barbara Weber
1,388,302US$10.1m1.51%no data
1.11%
Casdin Capital, LLC
1,188,349US$8.7m-9.1%0.78%
1.04%
Perceptive Advisors LLC
1,111,870US$8.1m-54%0.19%
1.03%
Geode Capital Management, LLC
1,097,102US$8.0m6%no data
0.92%
State Street Global Advisors, Inc.
978,938US$7.2m2.63%no data
0.79%
Soleus Capital Management, L.P.
847,145US$6.2m-56.1%0.69%
0.7%
Baker Bros. Advisors LP
750,000US$5.5m0%0.07%
0.66%
ArrowMark Colorado Holdings, LLC
708,385US$5.2m0%0.06%
0.66%
Bessemer Investment Management LLC
708,384US$5.2m0%0.01%
0.65%
MVA Associates, LLC
693,524US$5.1m-6.72%no data
0.59%
Samsara BioCapital LLC
630,000US$4.6m0%0.93%
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.